Researchers from Southern Medical University Discuss Findings in Personalized Medicine (Unveiling the Power of Gut Microbiome in Predicting Neoadjuvant Immunochemotherapy Responses in Esophageal Squamous Cell Carcinoma).

Researchers from Southern Medical University in Shenzhen, China, have conducted a study on the gut microbiome's role in predicting responses to neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma (ESCC). The study analyzed fecal samples from ESCC patients and healthy controls, identifying key microbial biomarkers that differentiated responders from nonresponders. The findings suggest that the gut microbiome could serve as a novel source of biomarkers for predicting treatment responses in ESCC, potentially enhancing personalized treatment strategies. The study was published in Research and was supported by various research foundations in China. [Extracted from the article]

Copyright of Drug Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)